Comprehensive genomic surveillance reveals transmission profiles of extensively drug-resistant tuberculosis cases in Para, Brazil.

ABSTRACT: Bedaquiline, an antimicrobial used to treat drug-resistant tuberculosis (DR-TB), was introduced in Brazil in October 2021. Monitoring the emergence and transmission of DR-TB is crucial for implementing public health to control the spread of DR strains of Mycobacterium tuberculosis. To measure its impact on the multi-drug treatment scheme in the state of Pará, we aimed to conduct genomic surveillance of DR-TB after bedaquiline was introduced in Brazil. Individuals treated for DR-TB between October 2021 and December 2022, in the reference hospital to treat DR-TB cases from the state of Pará, were included in the study. Clinical and bacteriological information was obtained from the National Laboratory Management Environment and the Special TB Treatment Information System. Genomic DNA w

SUBMITTER: Marcon DJ 

PROVIDER: S-EPMC11794272 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature